speaker-image

Jodie P. Morrison

CEO, Cadent Therapeutics

Cambridge, MA

speaker-image

Morrison is also a member of Cadent's board of directors. Previously, she was interim CEO at Keryx Bioppharmaceuticals Inc. , leading to the merger with Akebia Therapeutics, and acting COO at Syntimmune, acquires by Alexion. Earlier whe served as president and CEOI of Tokai Pharmaceuticals Inc.

  • October 2020

Added to: Ribon Therapeutics - Cambridge, MA

Ribon Therapeutics is a clinical state biotechnology company developing therapeutics targeting novel enzyme families that contribute to disease. Their lead program is an inhibitor in development for the treatment of cancer.